Close Menu

Valley fever

The test  runs on the GeneSTAT system, and has demonstrated 100 percent sensitivity, 99.6 percent specificity, and 100 percent reproducibility. 

The firm's real-time PCR-based GeneStat system was developed leveraging IP licensed exclusively from the Translational Genomics Research Institute.

NEW YORK (GenomeWeb News) – Molecular diagnostics company DxNA has received a $2.5M equity investment from an unnamed individual investor.

The company is developing and validating assays for difficult-to-treat and drug-resistant infectious diseases based primarily on targets, biomarkers, and PCR primers developed at the Translational Genomics Research Institute and Northern Arizona University.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.